跳至主要内容
临床试验/NCT02371785
NCT02371785已完成不适用

Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease

Corindus Inc.2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2015年2月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Corindus Inc.
入组人数
20
试验地点
2
主要终点
Device Technical Success

研究概览

简要总结

This study evaluates the performance of the CorPath 200 System to deliver guide wires and balloons to blockages in the arteries of the leg.

详细描述

The CorPath 200 System is currently marketed for remotely delivering guide wires, balloons and stents to blockages in the coronary arteries. This study will evaluate the feasibility of CorPath 200 System to deliver guide wires and balloons to blockages in non-coronary arteries.

Guide wires and balloons are delivered to blockages in the lower limbs manually by doctors.If this study shows that guide wires and balloons can be safely delivered to blockages in the lower limbs, then it will be an alternative for physicians.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • General Inclusion
  • At least 18 years of age;
  • Symptomatic disease: presence of critical limb ischemia (including tissue loss or rest pain), or lifestyle-limiting claudication requiring intervention in iliac and/or superficial femoral arteries;
  • The subject or the legally authorized representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent.
  • Angiographic Inclusion
  • Presence of superficial femoral artery and/or iliac stenosis (>50%) or occlusion of up to 50 mm in length as determined by angiogram prior to index interventional procedure.

排除标准

  • General Exclusion
  • Failure/inability/unwillingness to provide informed consent;
  • Target vessel has been previously treated with bypass;
  • Has an abdominal aortic aneurysm contiguous with the iliac artery target lesion;
  • Has contraindication to anticoagulation;
  • Has bleeding or a hypercoagulability disorder;
  • Thrombocytopenia;
  • Elevated international normalized ratio (>1.5);
  • Elevated serum creatinine (≥2.5 mg/dL);
  • Active infection;
  • Contraindication to contrast; or
  • Enrolled in concurrent clinical study.
  • Angiographic Exclusion
  • Target vessel:
  • shows evidence of previous dissection or perforation, or
  • has adjacent acute thrombus;
  • Lesion is highly calcified;
  • Lesion requires use of any atherectomy device during the procedure;
  • Has a pre-existing target artery aneurysm or perforation or dissection of the target artery prior to initiation of the interventional procedure.

研究组 & 干预措施

CorPath 200 System

Experimental

CorPath 200 System for remote delivery and manipulation of guidewires and balloon catheters during percutaneous vascular intervention.

干预措施: CorPath 200 System (Device)

结局指标

主要结局

Device Technical Success

时间窗: Procedure

Number of lesions for which there was technical success" as accurate and appropriate.

Adverse Events

时间窗: Procedure

No device-related serious adverse events during the procedure.

次要结局

  • Clinical Procedural Success(24-hours)
  • Total Procedure Time(Procedure)
  • Fluoroscopy Time(Procedure)
  • Contrast Volume(Procedure)
  • Interventional Procedure Time(Procedure)

研究者

发起方
Corindus Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验